Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egle

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 27, 2022
Transcriptomic Profiling Identifies CD8<sup>+</sup> T Cells in the Brain of Aged and Alzheimer's Disease Transgenic Mice as Tissue-Resident Memory T CellsBarbara Altendorfer, Michael Stefan Unger, Rodolphe Poupardin, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Cancer Research|February 4, 2016
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic LeukemiaPeter W Krenn, Sebastian W Hofbauer, Susanne Pucher, et al.
Ejhaem|July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
Acta Haematologica|February 25, 2024
Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the LiteratureThomas Parigger, Stephan Drothler, Christian Scherhäufl, et al.
Blood|January 21, 2018
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemiaJulia C Gutjahr, Eva Szenes, Lisa Tschech, et al.
British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study groupThomas Melchardt, Teresa Magnes, Clemens Hufnagl, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 27, 2022
Transcriptomic Profiling Identifies CD8<sup>+</sup> T Cells in the Brain of Aged and Alzheimer's Disease Transgenic Mice as Tissue-Resident Memory T CellsBarbara Altendorfer, Michael Stefan Unger, Rodolphe Poupardin, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Cancer Research|February 4, 2016
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic LeukemiaPeter W Krenn, Sebastian W Hofbauer, Susanne Pucher, et al.
Ejhaem|July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
Acta Haematologica|February 25, 2024
Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the LiteratureThomas Parigger, Stephan Drothler, Christian Scherhäufl, et al.
Blood|January 21, 2018
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemiaJulia C Gutjahr, Eva Szenes, Lisa Tschech, et al.
British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study groupThomas Melchardt, Teresa Magnes, Clemens Hufnagl, et al.
Pageof 11